journal article·2019-12-04Open access

microRNA-103 promotes LPS-induced inflammatory injury by targeting c-Myc in HK-2 cells

Wei Zhang, Wenyan Deng, Yingying Wang

Abstract

Aims microRNAs (miRNAs) occupy a vital position in diseases. This research aims to detect miR-103 influence on LPS-resulted HK-2 cells inflammation damage.Methods Cells were exposed to LPS for inducing injury. CCK-8 and flow cytometry were introduced to detect cell viability and apoptosis rate, respectively. ELISA, qRT-PCR and western blot were respectively used to explore inflammation factors production and relative proteins expression. The relationship between miR-103 and c-Myc was analysed through luciferase reporter assay.Results LPS led to significant inhibition of cell viability (p < .05) and proliferation-related proteins expression. It also increased the apoptosis rate (p < .05) and promoted inflammation cytokines overproduction (p < .001). Besides, miR-103 was elevated by LPS (p < .01), and aggravated LPS-induced damage above, while miR-103 inhibitor attenuated this impairment (p < .05, p < .01 or p < .001). However, c-Myc silence abolished miR-103 inhibitor protective effect on cell proliferation (p < .05), apoptosis (p < .01) and inflammation factors expression (p < .05 or p < .01), representing a negative relationship between them. Besides, the activity of NF-κB as well as JAK/STAT pathways was controlled by miR-103, also, mediated through c-Myc.Conclusions miR-103 mimic enhanced LPS-caused inflammation damage by silencing c-Myc in HK-2 cell line.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: MicroRNA in disease regulation · Circular RNAs in diseases · Cancer-related molecular mechanisms research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Nephrology, Jining No. 1 People’s Hospital

References (32)

Show source-provided references
1. 10.1016/S0140-6736(16)32064-510.1016/S0140-6736(16)32064-5 ↗
2. 10.1038/ki.2012.44010.1038/ki.2012.440 ↗
3. 10.7326/M17-264010.7326/M17-2640 ↗
4. 10.1155/2015/80635810.1155/2015/806358 ↗
5. 10.1007/s00018-017-2626-610.1007/s00018-017-2626-6 ↗
6. 10.1096/fj.11-18114910.1096/fj.11-181149 ↗
7. 10.1093/eurjhf/hft07810.1093/eurjhf/hft078 ↗
8. 10.1111/cmi.1258710.1111/cmi.12587 ↗
9. 10.18632/oncotarget.1344710.18632/oncotarget.13447 ↗
10. 10.1074/jbc.M109.07858410.1074/jbc.M109.078584 ↗
11. 10.4161/cc.10.13.1624910.4161/cc.10.13.16249 ↗
12. 10.1002/path.527310.1002/path.5273 ↗
13. 10.18632/oncotarget.1915410.18632/oncotarget.19154 ↗
14. 10.1038/nrc393210.1038/nrc3932 ↗
15. 10.1038/nrneph.2011.2610.1038/nrneph.2011.26 ↗
16. 10.1038/ki.2011.34510.1038/ki.2011.345 ↗
17. 10.1016/j.bone.2016.11.01610.1016/j.bone.2016.11.016 ↗
18. 10.1016/j.atherosclerosis.2017.06.04210.1016/j.atherosclerosis.2017.06.042 ↗
19. 10.1016/j.bbrc.2013.12.01610.1016/j.bbrc.2013.12.016 ↗
20. 10.1073/pnas.180771111510.1073/pnas.1807711115 ↗
21. 10.1016/j.bbagrm.2014.04.00310.1016/j.bbagrm.2014.04.003 ↗
22. 10.1002/stem.273410.1002/stem.2734 ↗
23. 10.1074/jbc.RA118.00246210.1074/jbc.RA118.002462 ↗
24. 10.1074/jbc.RA118.00628110.1074/jbc.RA118.006281 ↗
25. 10.1002/jcb.2633010.1002/jcb.26330 ↗
26. 10.18632/oncotarget.2604610.18632/oncotarget.26046 ↗
27. 10.2174/1574888X1366618030112493510.2174/1574888X13666180301124935 ↗
28. 10.1016/j.febslet.2012.06.00410.1016/j.febslet.2012.06.004 ↗
29. 10.1093/toxsci/kfs10610.1093/toxsci/kfs106 ↗
30. 10.1159/00048639810.1159/000486398 ↗
31. 10.1016/j.nut.2016.10.00310.1016/j.nut.2016.10.003 ↗
32. 10.1186/s10020-018-0045-210.1186/s10020-018-0045-2 ↗